AS Morbidities & Comorbidities

Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort

Background Disease activity may change over time in axial spondyloarthritis (axSpA). The objectives were to identify patterns of disease activity evolution…

About a third of early AS patients (first 3 years from diagnosis), in the natural course of the disease, will chart a severe destructive and debilitating course early in the disease due to high disease activity, resulting in work loss.

Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis

ASAS/EULAR recommendations for the management of AS [91]

AS is the prototypical member of the family of spondyloarthropathies, and is characterized by seronegativity, axial predominance and new bone formation, which underlie symptoms of inflammatory back pain, enthesopathy and extra-articular manifestations, including anterior uveitis, psoriasis and colit…

Complications from AS can come from the disease itself (pain, deformities, disability, cardiovascular risks) or its treatment (NSAIDs with gastrointestinal bleed and cardiovascular risks, anti-TNFs with infection risks).

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study

To investigate the risk of first-time acute coronary syndrome (ACS), stroke and venous thromboembolism (VTE) in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated spondyloarthritis (uSpA), compared to each other and to the general population (GP). This is a pro…

The unfortunate answer is “Yes”: AS is associated with increased risk for heart attack, stroke and deep vein thrombosis. As in other chronic inflammatory conditions like RA, AS is not merely a pain condition which you can dismiss by being stoic.

Statin use linked with reduced mortality among patients with AS and PsA

Image result for statin

WASHINGTON — Statin use was associated with a 32% reduction in mortality in a large cohort of…

Yes, there is solid proof that statins reduce mortality in those with increased risk from chronic inflammatory conditions like AS and PsA.